Loading...
Market
Story
FDA Expands Approval of GSK's RSV Vaccine for High-Risk Adults Aged 50 to 59
Jun 7, 2024, 10:25 PM
The U.S. Food and Drug Administration (FDA) has expanded the approval of GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, to include high-risk adults aged 50 to 59. This marks the first time a vaccine for RSV has been approved for this age group. Previously, the vaccine was only approved for adults 60 and older. The expanded approval, announced on Friday, aims to protect at-risk adults and potentially gives GSK an edge over competitors Pfizer and Moderna, especially ahead of the autumn season when respiratory viruses spread rapidly.
View original story
Similar markets
Moderna leads • 33%
GSK leads • 33%
Pfizer leads • 33%
More than 20% • 50%
20% or less • 50%
Below 50% • 25%
50% to 60% • 25%
60% to 70% • 25%
Above 70% • 25%
Positive impact • 33%
Negative impact • 33%
No significant impact • 34%
Spikevax • 33%
RSV vaccine • 33%
Other • 34%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
Above $1.5 billion • 25%
More than GSK and Pfizer combined • 50%
Less than GSK and Pfizer combined • 50%
Novavax/Sanofi leads • 33%
Pfizer/BioNTech leads • 33%
Moderna leads • 33%
Moderna gains highest market share • 33%
Pfizer retains highest market share • 33%
BioNTech gains highest market share • 33%